Solutions in next week's Sunday Mirror ABCDEFGHIJKLMNOPQRSTUVWXYZ BEXTRA
LETTER LINE: Call 0903 655 6060 (60p/min) for up to five extra letters.
The company's investors had claimed that Pfizer made misleading statements connected to a government investigation of Pfizer's off-label marketing practices of Bextra
and other drugs, an investigation that eventually led to a $2.
was pulled from the market; Celebrex stayed on shelves but only with a host of grim new warnings about the drug's dangers.
NYSE: PFE) struck in 2009 to settle an investigation of improper drug marketing related to its Bextra
According to the government, Pfizer promoted the sale of Bextra
for uses and dosages the FDA specifically refused to approve due to concerns over patient safety.
3bn in the year-ago quarter related to the resolution of certain investigations concerning Bextra
and various other products, in addition to the favourable impact of lower costs incurred in connection with the company's cost-reduction initiatives in 2009.
3 billion to settle such a marketing case involving the painkiller Bextra
and three of its other medications.
Justice Department, Pharmacia & Hpjohn Company pleaded guilty to a felony violation of the Food, Drag and Cosmetic Act for misbranding Bextra
, its anti-inflammatory drug, with the intent to defraud or mislead.
3 billion charge late last year to resolve allegations involving Bextra
and other drugs, but did not provide details at the time.
Tony West, the assistant attorney general at the US justice department, said Pfizer had asked the Food and Drug Administration if it could promote the sale of Bextra
, an anti-inflammatory drug, for certain other uses and in doses higher than the approved maximum.
Pfizer paid $60 million to 33 states in October to settle claims it improperly marketed its Bextra
and Celebrex pain relievers.
3 billion charge to resolve an investigation into Bextra
marketing practices, as well as other investigations.